Abstract:Objectives To explore the clinical significance of tyrosine kinase receptor RON mRNA expression and it's splicing variant in bladder tumors. Methods Sixty-three cases of transitional cell carcinoma of the bladder (TCCB), including 30 cases of pathological grade I , 15 cases of pathological grade Ⅱ and 18 cases of pathological grade Ⅲ (44 cases of clinical stage Tis + T1, 15 cases of T2 + T3 +T4), 7 inverted papilloma of the bladder ( IPB), 9 cases of papillary urothelial neoplasm of low malignant potential (PUNLMP) and 12 cases of normalbladder mucosa RT-PCR was employed with the internal standard (GAPDHmRNA) to detect the expression of RON mRNA. PCR and direct sequencing was then utilized to identify the potential RON mRNA splicing variants. Finally, the variants' positive rates of expression were analyzed among the different tissues, diverse TCCB pathological grades and clinical stages. Results The expression levels of RON mRNA/GAPDH mRNA among TCCB, IPB, PUNLMP and normal control were 4. 9 × 10-3 ( 1. 8 × 10-3-1.0 × 10-2 ), 3. 8 × 10-3 (2. 4 × 10-3-1.7 × 10-2 ), 4. 9 ×10 -3 ( 1.7 × 10 -3-1.1 × 10 -2 ) and 1.0 × 10-3 (4. 5 × 10-4-2. 8 × 10-3 ) respectively. The difference had a statistical significance (x2K-W = 17. 278 ,P ＜0. 05 ). The expression levels among pathological grade I, Ⅱ and Ⅲ were 3.7 × 10-3( 1.3 × 10-3-7.5 × 10-3) , 4. 9 × 10-3(1.9 × 10-3-1.1 × 10-2) and 8.9 × 10-3(2. 7 ×10 -3-8.0 × 10 -2 ) respectively. The erpression levels among the clinical stage Tis + T1 and T2 + T3 + T4were 3.5 × 10-3 ( 1.2 × 10 -3-7. 7 × 10-3 ) and 9. 7 × 10 -3 ( 2. 9 × 10-3-5. 3 × 10-2 ). The differences between expression levels were of statistical significance among the different pathological grades ( x2k-W =7. 341, P ＜0. 05 ) and clinical stages ( Z = - 2. 306, P ＜ 0. 05 ). The positive rates of exon 11deletion(E11△) in TCCB, IPB and PUNLMP were 71％ (45/63), 57％ (4/7) and 67％ (6/9) respectively, andthe total positive rate in bladder tumor tissues was 70％. Meanwhile, expression of the novel RON variant wesnot detected in the normalbladder mucosa. The positive expression rate of E1 1△ has no significant correlationamong the different clinical pathological tissues (x2 = 0. 620, P ＞ 0. 05 ). There was no statistical significancein expression positive rate between different pathological grades ( Z =0. 221, P ＞0. 05 ) and clinical stages( Z = 0. 538, P ＞ 0. 05) as well. A novel RON splice variant, deletion of RON exon 11 3 476 - 3 539 ( E3476 -3539△) was fond in the pathological tissue. The positive expression rates of E3 476 -3 539 in TCCB,IPB and PUNLMP were 57％ (36/63), 43％ (3/7) and 56％ (5/9) respectively, and the total positive expression rate was 56％ (44/79). The positive rates of E3 476 -3 539△ in pathological grade I , Ⅱ and Ⅲ were 40％ ( 12/30), 67％ (10/15) and 78％ (14/18), and it's positive rates in clinical stage Tis +T1and T2 +T3 + T4 were 48％ (21/44) and 80％ (12/15). The differences in each group had significantly statistical significance ( Z = 7. 285, 5. 041, P ＜ 0. 05 ) . However, the positive rates amongdifferent pathological tissues had no significance (x2 = 0. 517, P ＞ 0. 05 ). Conclusions The expression level of RON mRNA is significantly associated with histological grading and clinical stage. RON may play an important role in the progression ofTCCB. Compared with the normal control, the increased RON variant expression may contribute to the carcinogenesis of the bladder tumor.

Study of structural polymorphism of bcl-6 gene non-coding exon and its protein expression in transitional cell carcinomas

Study of the Expression of CK20 and Ki67 on Cystitis Glandularis of the Urinary Bladder

Significance of Tyrosine Kinase Receptor Gene and Its Variant Expressions in Bladder Tumor Tissues

BCL6 Gene Mutations in Transitional Cell Carcinomas

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in transitional cell carcinoma of bladder and their correlation

The Expression of Bcl-2 and Bcl-6 Protein in Normal and Malignant Transitional Epithelium

Altered γ-catenin expression in bladder transitional cell carcinoma and its implication

DNA Polymorphisms in Exon 1 and Promoter of the CDH1 Gene and Relevant Risk of Transitional Cell Carcinoma of the Urinary Bladder

Expression of PTEN in human transitional cell carcinoma of bladder and its clinical significance

EXPRESSION AND CLINICAL SIGNIFICANCE OF CYCLIN G1 AND CYCLIN G_2 IN TRANSITIONAL CELL CARCINOMA OF BLADDER

Expression of PCNA in Human Bladder Transitional Cell Carcinoma and Its Clinical Significance

Relationship between an insertion/deletion polymorphism in noncoding region of exon1 of CDH1 Gene and susceptibility of transitional cell carcinoma of the bladder

Gene expression profile changes in human bladder superficial transitional cell carcinoma

Expression of RASSF1A, cyclin D1, Bcl-2 and their significance in transitional cell carcinoma fo bladder

Study of aberrant methylation of PTEN gene promoter and its expression in transitional cell carcinoma of the bladder

A Correlation Study of Single Nucleotide Polymorphisms in Exon 13 of E-cadherin Gene CDH1 with Transitional Cell Carcinoma of the Bladder

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

Expressions of P16 Protein and PCNA in Transitional Cell Carcinoma of the Urinary Bladder and Their Implications

Expressions of RASSF1A,Cyclin D1,Bcl-2 and Their Significance in Transitional Cell Carcinoma of Bladder

Expression and clinical significance of E-cadherin-catenin complex in human transitional cell carcinoma of bladder

Expression of X-linked Inhibitor of Apoptosis Protein in Transitional Cell Carcinoma and the Clinical Significance